Selected article for: "acute ARDS respiratory distress syndrome and sepsis shock"
Author: Laroye, Caroline; Gibot, Sébastien; Huselstein, Céline; Bensoussan, Danièle
Title: Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID‐19
  • Cord-id: 14egr2t8
  • Document date: 2020_8_18
    • ID: 14egr2t8
    Snippet: Sepsis is defined as life‐threatening organ dysfunction caused by a deregulated immune host response to infection. The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has highlighted this multifactorial and complex syndrome. The absence of specific treatment neither against SARS‐CoV‐2 nor against acute respiratory distress syndrome (ARDS), the most serious stage of this infection, has emphasized the need to find alternative treatments. Several therapeutics
    Document: Sepsis is defined as life‐threatening organ dysfunction caused by a deregulated immune host response to infection. The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has highlighted this multifactorial and complex syndrome. The absence of specific treatment neither against SARS‐CoV‐2 nor against acute respiratory distress syndrome (ARDS), the most serious stage of this infection, has emphasized the need to find alternative treatments. Several therapeutics are currently tested and among them, mesenchymal stromal cells. These cells, already used in preclinical models of ARDS, sepsis, and septic shock and also in few clinical trials appear well‐tolerated, promising, but many questions remain unanswered.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and adipose tissue: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and low immunogenicity: 1, 2, 3
    • acute ards respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute ards respiratory distress syndrome and low mortality rate: 1, 2, 3, 4
    • adaptive immunity and adipose tissue: 1
    • adaptive immunity and low mortality: 1, 2, 3
    • adaptive immunity and macrophage inflammatory phenotype: 1
    • adipose tissue and low immunogenicity: 1
    • adipose tissue and low mortality: 1, 2